Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06290544

Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus (CARDT1)

This is a multicenter prospective collection of data with diagnostic procedures different from standard clinical care in a specific cohort of patients, aimed to evaluate cardiovascular risk stratification with the European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines and "The Steno Type 1 Risk Engine" algorithm. The correlation between CVD risk, atherosclerosis, and microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) will then be evaluated, and the impact of glycemic variability and other glucose metrics on vascular damage will be characterized. The investigators plan to enroll at least 200 consecutive type 1 diabetes mellitus (T1DM) patients who meet all the inclusion criteria and none of exclusion criteria.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

IRCCS Centro Cardiologico Monzino, Milan, Italy

Loading trial locations.

About this study

Patients with type 1 diabetes mellitus will be identified in the electronic medical records, and their clinical, anthropometric, and laboratory data, including markers of glycemic variability and other blood glucose metrics, will be collected. Cardiovascular risk will then be assessed using the stratification proposed by ESC/EASD and The Steno Type 1 Risk Engine.

As suggested by the guidelines, according to cardiovascular risk, participants will perform a coronary CT scan in order to investigate coronary anatomy, to study the atherosclerotic plaque morphology, to assess high-risk plaque characteristics, and in case of obstructive coronary artery disease, to investigate myocardial perfusion by adenosine infusion to assess both ischemia and microcirculation dysfunction. Noninvasive B-mode ultrasonography of the supra-aortic trunks will assess for signs of carotid atherosclerosis (i.e., carotid intima media thickness - c-IMT - and carotid plaques). Ankle-arm index (ABI), a noninvasive cardiovascular bio-marker, will provide information on peripheral arterial disease. Endothelial function will be also assessed using the ENDO-PAT 2000 instrument which measures endothelial dysfunction with a peripheral arterial tone detection method.

For the purpose of assessing participants' nutritional habits, participants will be asked to complete the Food Frequency Questionnaire (FFQ) the week prior the visit; once the FFQ will be completed an interview with the nutritionist will be scheduled in order to review and to ascertain its completeness; in addition, the PREDIMED questionnaire for calculating the Mediterranean Diet Adherence Screener score (MEDAS) will be administered to assess adherence to the Mediterranean diet.

An interview with the psychologist will be planned. During that visit the participant will receive information about the rationale of the study regarding psychological aspects, the questionnaires that will be administered and how to fill them out correctly online via the Qualtrics EU platform. The Iowa Gambling Task (IGT) test will then be administered.

Finally, biological samples will be collected for future genomic and epigenetic analyses associated with different cardiovascular disease (CVD) phenotypes and outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of type 1 diabetes mellitus.
  • Age ≥ 18 years.
  • Signed Informed consent

Exclusion criteria

  • Age < 18 years.
  • Pregnancy in progress.
  • Type 2 diabetes mellitus.
  • Secondary diabetes

Treatment and study plan

Standard of care plus additional examinations

Other

The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies

Primary outcomes

  1. Stratify cohort of type 1 diabetes patient according to ESC/EASD 2019 guidelines.

    Time frame: 5 years

    Evaluation of cardiovascular risk class for type 1 diabetic patients using ESC/EASD stratification according to disease duration

  2. Stratify cohort of type 1 diabetes patient according to the Steno Type 1 Risk Engine (ST1RE).

    Time frame: 5 years

    Evaluation of cardiovascular risk class for type 1 diabetic patients using The Steno Type 1 Risk Engine algorithm

  3. Prevalence of cardiovascular disease in type 1 diabetes patients

    Time frame: 5 years

    Prevalence of cardiovascular disease in T1DM cohort defined as one of the following:

    • acute mycardial infarction
    • ischemic stroke
    • peripheral artery disease
    • coronary, carotid or peripheral artery revascularization
    • presence of clinically significant stenosis in coronary CT and/or in carotid ultrasound assessment.

Secondary outcomes

  1. Prevalence of diabetic retinopathy

    Time frame: 5 years

    Prevalence of diabetic retinopathy

  2. Prevalence of diabetic nephropathy

    Time frame: 5 years

    Prevalence of diabetic nephropathy

  3. Prevalence of diabetic neuropathy

    Time frame: 5 years

    Prevalence of diabetic neuropathy

  4. CT-derived calcium score

    Time frame: 5 years

    CT-derived calcium score

  5. Carotid intima-media thickness

    Time frame: 5 years

    Carotid intima-media thickness

  6. Prevalence of endothelial dysfuntion (evaluated using peripheral arterial tone detection method)

    Time frame: 5 years

    Prevalence of endothelial dysfuntion (evaluated using peripheral arterial tone detection method)

  7. Stratify type 1 patient cohort by Food Frequency Questionnaire (FFQ)

    Time frame: At enrollment

    Stratify type 1 patient cohort by Food Frequency Questionnaire (FFQ)

  8. Stratify type 1 patient cohort by the Mediterranean Diet Adherence Screener score (MEDAS)

    Time frame: At enrollment

    Stratify type 1 patient cohort by the Mediterranean Diet Adherence Screener score (MEDAS)

  9. Stratify type 1 patient cohort by psychological profiles using psychological validated questionnaires.

    Time frame: 5 years

    Stratify type 1 patient cohort by psychological profiles using psychological validated questionnaires.

  10. Stratify type 1 patient cohort by lipid profile

    Time frame: 5 years

    Stratify type 1 patient cohort by lipid profile

  11. Stratify type 1 patient by glucose control using HbA1c and Ambulatory Glucose Profile metrics.

    Time frame: 5 years

    Stratify type 1 patient by glucose control using HbA1c and Ambulatory Glucose Profile metrics.

Study contacts

Contact information is provided by the study sponsor or research team.

Maurizio Rondinelli, MD

CONTACT

[email protected]

+390258002040

Stefano Genovese, MD

CONTACT

[email protected]

+390258002327

Sponsors and collaborators

Lead sponsor

Centro Cardiologico Monzino

Other

Registry information

Official study title

Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus - CARDT1

Acronym: CARDT1

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Mar 4, 2024
Registry last updated
Mar 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.